Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone.

Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Abstract Text:

Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer research

VOLUME: 16

Page Numbers: 167-70

Journal Abbreviation: Cancer Res.

ISSN: 0008-5472

DAY: 3

MONTH: Feb

YEAR: 1956

Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Keywords Mesh Terms:

KEYWORDS: Leukemia, Experimental

MESH TERMS:

Chemical & Substance for Abstract: Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone.

AFFILIATION:

Country: Not Available

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone Related Publications

• A conceptual model for the study of the health action process.
• Carbamates in the chemotherapy of leukemia; observation of a possible antileukemic synergism between urethane and methyl-bis (beta-chloroethyl) amine.
• Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774).
• Combination therapy: some concepts and results.
• Decentralized medical education in rural communities: the circuit rider connection.
• Dietary intake and parents' perception of mealtime behaviors in preschool-age children with autism spectrum disorder and in typically developing children.
• Drug evaluation in experimental tumor systems: potential and limitations in 1961.
• Experimental adjuvant chemotherapy: an overview.
• Experimental clinical cancer chemotherapy. Philosophy at the preclinical level.
• Formation of giant solvation shells around fulleride anions in liquid ammonia.
• HYPOTHYROIDISM IN DIABETICS TREATED WITH SULPHONYLUREA.
• Homelessness and substance use among alcohol abusers following participation in project H&ART.
• Identification of Adducts Formed by Reaction of N-Acetoxy-3,5-dimethylaniline with DNA.
• Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.
• Integration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection.
• Observations of the retiring chairman of the Cancer Chemotherapy Review Board.
• Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone.
• Physician behavior modification using claims data: tetracycline for upper respiratory infection.
• Proceedings: Successes and failures at the preclinical level; where now?
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.
• Steerable real-time sonographically guided needle biopsy.
• Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster.
• Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755.
• The "sensitivity" of resting and dividing cells.
• Treating the chemically dependent health professional.